Although many studies have documented the tumor-promoting role of hepsin in several types of malignancies, little is known about its clinical and biological significance in breast cancer.
Materials and Methods
Hepsin expression was examined in 4 pairs of fresh breast tumor samples and corresponding nontumor breast tissues by Western blotting. Immunohistochemistry for hepsin was performed on an additional cohort of 215 archival breast cancer samples. The clinical significance of hepsin expression was analyzed. Knockdown of hepsin expression was performed in 2 breast cancer cell lines, MDA-MB-231 and HER18, with a high abundance of endogenous hepsin, and the effects of hepsin silencing on cell invasion and proliferation were evaluated.
Results
Hepsin was aberrantly overexpressed in breast cancer tissues relative to adjacent nontumor tissues. Its overexpression was significantly associated with tumor stage (P = 0.037), lymph node metastasis (P = 0.010), estrogen receptor positivity (P = 0.019), and progesterone receptor positivity (P < 0.0001) in patients with breast cancer. Down-regulation of hepsin expression by small interfering RNA (siRNA) significantly reduced cell proliferation and invasion in both the MDA-MB-231 and HER18 cells compared to nonspecific control small interference RNA.
Conclusion
Our data demonstrate that hepsin expression is frequently up-regulated in breast cancer tissues, which is associated with tumor growth and progression. Thus, inhibition of hepsin expression might be of therapeutic significance.
ParkerB, SukumarS.Distant metastasis in breast cancer: molecular mechanisms and therapeutic targets. Cancer Biol Ther. 2003;2:14–21.
2.
ChambersAF, GroomAC, MacDonaldIC.Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–572.
3.
FidlerIJ.The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453–458.
4.
LiottaLA, SteegPS, Stetler-StevensonWG.Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327–336.
5.
YoonSO, ParkSJ, YunCH, . Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol. 2003;36:128–137.
6.
TanimotoH, YanY, ClarkeJ, . Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res. 1997;57:2884–2887.
7.
KlezovitchO, ChevilletJ, MirosevichJ, . Hepsin promotes prostate cancer progression and metastasis. Cancer Cell. 2004;6:185–195.
8.
LeytusSP, LoebKR, HagenFS, . A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry. 1988;27:1067–1074.
XuanJA, SchneiderD, ToyP, . Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res. 2006;66:3611–3619.
14.
BetsunohH, MukaiS, AkiyamaY, . Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci. 2007;98:491–498.
15.
RoemerA, SchwettmannL, JungM, . The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers?J Urol. 2004;172:2162–2166.
16.
HarveyJM, ClarkGM, OsborneCK, . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–1481.
17.
CarlsonRW, MoenchSJ, HammondME, . HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006;4(suppl 3):S1–S22.
18.
GreeneFL, PageDL, FlemingID, . AJCC Cancer Staging Manual. New York, NY: Springer; 2002:223–240.
19.
CroninPA, WangJH, RedmondHP.Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4. BMC Cancer. 2010;10:225.
20.
LiX, ShenL, ZhangJ, . Degradation of HER2 by Cbl-based chimeric ubiquitin ligases. Cancer Res. 2007;67:8716–8724.
21.
LivakKJ, SchmittgenTD.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408.
22.
StephanC, YousefGM, ScorilasA, . Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol. 2004;171:187–191.
23.
MatsuoT, NakamuraK, TakamotoN, . Expression of the serine protease hepsin and clinical outcome of human endometrial cancer. Anticancer Res. 2008;28:159–164.
24.
TozluS, GiraultI, VacherS, . Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer. 2006;13:1109–1120.
25.
FisherB, RedmondC, BrownA, . Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol. 1983;1:227–241.
26.
RavdinPM, GreenS, DorrTM, . Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992;10:1284–1291.
27.
NandanaS, Ellwood-YenK, SawyersC, . Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model. Prostate. 2010;70:591–600.
28.
MiaoJ, MuD, ErgelB, . Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model. Int J Cancer. 2008;123:2041–2047.
29.
LiW, WangBE, MoranP, . Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis. Cancer Res. 2009;69:8395–8402.
30.
HerterS, PiperDE, AaronW, . Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J. 2005;390:125–136.
31.
MoranP, LiW, FanB, . Pro-urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem. 2006;281:30439–30446.
32.
TripathiM, NandanaS, YamashitaH, . Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. J Biol Chem. 2008;283:30576–30584.
33.
CecchiF, RabeDC, BottaroDP.Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer. 2010;46:1260–1270.
34.
ElliottBE, HungWL, BoagAH, . The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can J Physiol Pharmacol. 2002;80:91–102.
35.
JiangW, HiscoxS, MatsumotoK, . Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol. 1999;29:209–248.
36.
Sheen-ChenSM, LiuYW, EngHL, . Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:715–717.
37.
HuangHY, JiangZF, LiQX, . Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator. Cancer Invest. 2010;28:689–697.
38.
NakamuraK, TakamotoN, AbarzuaF, . Hepsin inhibits the cell growth of endometrial cancer. Int J Mol Med. 2008;22:389–397.
39.
Torres-RosadoA, O'SheaKS, TsujiA, . Hepsin, a putative cell-surface serine protease, is required for mammalian cell growth. Proc Natl Acad Sci U S A. 1993;90:7181–7185.
40.
NakamuraK, NasuY, HongoA, . Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines. Int J Oncol. 2006;28:393–398.
41.
SrikantanV, ValladaresM, RhimJS, . HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res. 2002;62:6812–6816.
